Rhabdoid Tumor Clinical Trials

4 recruiting

Rhabdoid Tumor Trials at a Glance

15 actively recruiting trials for rhabdoid tumor are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 1 with 12 trials, with the heaviest enrollment activity in Washington D.C., Palo Alto, and Memphis. Lead sponsors running rhabdoid tumor studies include St. Jude Children's Research Hospital, Seattle Children's Hospital, and Baylor College of Medicine.

Browse rhabdoid tumor trials by phase

Treatments under study

About Rhabdoid Tumor Clinical Trials

Looking for clinical trials for Rhabdoid Tumor? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Rhabdoid Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Rhabdoid Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting
Phase 2

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

Solid TumorWilms TumorRhabdoid Tumor+4 more
Memorial Sloan Kettering Cancer Center45 enrolled16 locationsNCT05985161
Recruiting
Phase 1

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Soft Tissue SarcomaMelanomaCarcinoma+13 more
St. Jude Children's Research Hospital48 enrolled1 locationNCT04897321
Recruiting
Phase 1Phase 2

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Recurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRecurrent Solid Tumor+19 more
St. Jude Children's Research Hospital90 enrolled10 locationsNCT04901702
Recruiting
Phase 1Phase 2

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

OsteosarcomaEwing SarcomaNeuroblastoma+4 more
Milton S. Hershey Medical Center289 enrolled10 locationsNCT06465199
Recruiting
Phase 1

Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

Germ Cell TumorChoroid Plexus CarcinomaCentral Nervous System Tumor+8 more
Seattle Children's Hospital90 enrolled1 locationNCT04185038
Recruiting
Phase 1

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

Liver CancerRhabdomyosarcomaWilms Tumor+3 more
Baylor College of Medicine24 enrolled1 locationNCT04715191
Recruiting
Phase 2

Study to ONO-4538 in Patients With Rhabdoid Tumor

Rhabdoid Tumor
Ono Pharmaceutical Co., Ltd.23 enrolled5 locationsNCT06622941
Recruiting
Phase 1Phase 2

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

OsteosarcomaEwing SarcomaNeuroblastoma+10 more
University of Florida27 enrolled1 locationNCT06625190
Recruiting
Phase 1

Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)

PineoblastomaEmbryonal Tumor With Multilayered RosettesEpendymoma+3 more
Children's National Research Institute12 enrolled1 locationNCT06193759
Recruiting
Phase 1

Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

Hepatocellular CarcinomaRhabdomyosarcomaWilms Tumor+7 more
Seattle Children's Hospital21 enrolled1 locationNCT07148050
Recruiting
Phase 1

GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults

Pediatric Brain TumorPineoblastomaMedulloblastoma+7 more
Stanford University18 enrolled1 locationNCT07087002
Recruiting
Phase 1

Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

Central Nervous System NeoplasmsGlioblastomaHigh Grade Glioma+4 more
St. Jude Children's Research Hospital48 enrolled1 locationNCT05835687
Recruiting
Phase 1

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Central Nervous System NeoplasmsGlioblastomaOligodendroglioma+20 more
Jazz Pharmaceuticals102 enrolled1 locationNCT04541082
Recruiting
Phase 1

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

Hepatocellular CarcinomaRhabdomyosarcomaWilms Tumor+5 more
Baylor College of Medicine21 enrolled1 locationNCT06198296
Recruiting

Molecular Basis of Pediatric Liver Cancer

Hepatocellular CarcinomaLiver Malignant TumorsHepatoblastoma+3 more
University of Pittsburgh1,600 enrolled1 locationNCT03959800